0001582746-19-000001.txt : 20190211 0001582746-19-000001.hdr.sgml : 20190211 20190211171404 ACCESSION NUMBER: 0001582746-19-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190211 DATE AS OF CHANGE: 20190211 EFFECTIVENESS DATE: 20190211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-332606 FILM NUMBER: 19586488 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 D 1 primary_doc.xml X0708 D LIVE 0001341235 Aldeyra Therapeutics, Inc. 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA MASSACHUSETTS 02421 781-761-4904 DELAWARE Aldexa Therapeutics, Inc. Neuron Systems Inc Corporation true Todd Brady 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer Director Joshua Reed 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer David L. Clark 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer David McMullin 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer Martin J. Joyce 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Gary Phillips 131 Hartwell Avenue Lexington MA MASSACHUSETTS 02421 Director Ben Bronstein 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Neal Walker 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Jesse I. Treu 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Richard Douglas 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Director Stephen Machatha 131 Hartwell Avenue Suite 320 Lexington MA MASSACHUSETTS 02421 Executive Officer Biotechnology Decline to Disclose 06b false 2019-01-28 false true true The Company acquired Helio Vision, Inc. ("Helio"), as further described in the Company's Form 8-K filed with the SEC on January 29, 2019. 0 25000000 10000000 15000000 13(a) includes the consideration issuable upon the achievement of certain milestones in connection with the transaction. 13(b) represents 1,150,990 shares of common stock issued to the former securityholders and an advisor of Helio. false 37 0 0 0 false Aldeyra Therapeutics, Inc. /s/ Joshua Reed Joshua Reed Chief Financial Officer 2019-02-11